神経疾患用デジタル治療の世界市場：2025年～2033年

世界の神経疾患用デジタル治療の市場規模は、2024年に2億4,694万米ドルに達し、2033年には5億436万米ドルに達すると予測されており、予測期間の2025年～2033年のCAGRは8.3%になる見込みです。

神経疾患用デジタル治療とは、モバイルアプリ、ソフトウェアプログラム、仮想現実（VR）、ウェアラブル、その他の接続デバイスなどのデジタルプラットフォームを活用して、神経疾患の予防、管理、治療を行うエビデンスに基づく治療介入を指します。これらの治療は、多くの場合、人工知能（AI）、機械学習（ML）、ビッグデータ解析、神経刺激などの先進技術を駆使して、オーダーメイドのリアルタイムかつ非侵襲的な治療を提供します。

デジタル治療は、神経疾患によって影響を受ける認知機能、運動機能、行動機能に焦点を当て、正確で個別化された患者中心の介入を提供するように設計されています。従来の治療と併用することも、単独の治療として使用することも可能で、自己管理、リハビリテーション、症状モニタリング、行動修正が含まれることもあります。これらのデジタル・ソリューションは、従来の治療と比較して、よりアクセスしやすく、利便性が高く、コストを削減しながら、臨床転帰を改善することを目指しています。

在宅ケアと遠隔患者モニタリングへのシフトは、神経疾患用デジタル治療市場の成長を大きく後押ししており、予測期間中も市場を牽引するとみられます。在宅治療により、患者は頻繁な通院の必要なく治療を受けることができ、パーキンソン病、アルツハイマー病、多発性硬化症などの慢性神経疾患の患者にとっては特に重要です。デジタル治療を活用することで、患者はモバイルアプリやウェアラブル、その他のデジタルプラットフォームを使って自宅で症状を管理することができます。

例えば、Akili InteractiveのADHD用デジタル治療EndeavorRxは、自宅で使用できるソリューションの一例で、患者はクリニックに通院することなく治療を受けることができ、患者とヘルスケア提供者双方の負担が軽減されます。

遠隔患者モニタリングは地理的な障壁を克服するのに役立ち、地方や十分なサービスを受けていない地域の患者が長距離を移動することなく高度な神経学的治療を受けられるようにします。症状追跡や治療アドヒアランスのためのアプリを含むデジタル治療ソリューションは、どこでも使用することができ、専門的治療へのアクセスのギャップを埋めることができます。

デジタル治療は、自己管理アプリ、リマインダー、個別化された介入などのツールを提供することで、患者の関心を引くように設計されています。これにより、特に長期管理が必要な慢性神経疾患において、患者の治療レジメンへのアドヒアランスが向上します。多くのデジタルソリューションの双方向性やゲーミフィケーションの性質は、患者が処方された治療レジメンを継続しやすくし、定期的に進捗状況を把握しやすくすることで、エンゲージメントを高めます。

例えば、2023年10月、BeCareLinkは、神経疾患のスクリーニングとモニタリングのための一般的な神経学的検査をサポートする新しい定量的かつ人工知能（AI）対応のアプリを発表しました。BeCare Neuro Linkと呼ばれるこの新しいモバイルアプリは、神経学的患者または神経学的疾患の可能性のある患者を遠隔で客観的かつ包括的に評価することを目的としています。

当レポートでは、世界の神経疾患用デジタル治療市場について調査し、市場の概要とともに、製品タイプ別、疾患タイプ別、エンドユーザー別、地域別動向、競合情勢、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 市場のイントロダクションと範囲

第2章 エグゼクティブの洞察と重要なポイント

第3章 市場力学

• 影響要因
  • 促進要因
  • 抑制要因
  • 機会
  • 影響分析

第4章 戦略的洞察と業界の展望

• 市場のリーダーと先駆者
• CXOの視点
• 最新の開発とブレークスルー
• ケーススタディ/進行中の調査
• 規制と償還の情勢
• ポーターのファイブフォース分析
• サプライチェーン分析
• 特許分析
• SWOT分析
• アンメットニーズとギャップ
• 市場参入と拡大のための推奨戦略
• シナリオ分析ベストケース、ベースケース、ワーストケースの予測
• 価格分析と価格動向
• キーオピニオンリーダー

第5章 神経疾患用デジタル治療市場、製品タイプ別

• ソフトウェアセラピューティクス
• ウェアラブルデバイス

第6章 神経疾患用デジタル治療市場、疾患タイプ別

• 神経変性疾患
• 精神疾患
• 脳卒中および脳血管障害
• 睡眠障害
• 認知障害
• その他

第7章 神経疾患用デジタル治療市場、エンドユーザー別

• 病院
• 専門クリニック
• 神経リハビリテーションセンター
• 在宅ケア
• その他

第8章 神経疾患用デジタル治療市場、地域別市場分析と成長機会

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他
• ラテンアメリカ
  • メキシコ
  • ブラジル
  • アルゼンチン
  • その他
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他
• 中東・アフリカ

第9章 競合情勢と市場ポジショニング

第10章 企業プロファイル

• Akili, Inc.
• Click Therapeutics, Inc.
• BigHealth
• Apple Inc.
• MindMaze Inc
• NeuroPace, Inc.
• NeurologyToolKit
• Matoph Labs eU
• Fullpower Technologies, Inc.
• Neybox Digital Ltd.

第11章 仮定と調査手法

第12章 付録

The global digital therapeutics for neurological disorders market reached US$ 246.94 million in 2024 and is expected to reach US$ 504.36 million by 2033, growing at a CAGR of 8.3% during the forecast period 2025-2033.

Digital therapeutics for neurological disorders refer to evidence-based therapeutic interventions that leverage digital platforms such as mobile apps, software programs, virtual reality (VR), wearables and other connected devices to prevent, manage or treat neurological conditions. These treatments are often powered by advanced technologies such as artificial intelligence (AI), machine learning (ML), big data analytics and neurostimulation to deliver tailored, real-time and often non-invasive care.

Digital therapeutics are designed to provide precise, personalized and patient-centered interventions, focusing on cognitive, motor and behavioral functions that are impacted by neurological disorders. They can be used in conjunction with traditional treatments or as standalone therapies and may involve self-management, rehabilitation, symptom monitoring or behavior modification. These digital solutions aim to improve clinical outcomes while offering greater accessibility, convenience and reduced costs compared to traditional treatments.

Market Dynamics: Drivers & Restraints

Shift Towards Home-Based Care & Remote Patient Monitoring

The shift towards home-based care & remote patient monitoring is significantly driving the growth of the digital therapeutics for neurological disorders market and is expected to drive the market over the forecast period. Home-based care allows patients to receive treatment without the need for frequent hospital visits, particularly important for patients with chronic neurological conditions like Parkinson's Disease, Alzheimer's or Multiple Sclerosis. By leveraging digital therapeutics, patients can manage their symptoms at home using mobile apps, wearables or other digital platforms.

For instance, Akili Interactive's EndeavorRx, a digital therapeutic for ADHD, is an example of a solution that can be used at home, allowing patients to receive therapy without the need for in-clinic visits, reducing the burden on both patients and healthcare providers.

Remote patient monitoring helps overcome geographic barriers, allowing patients in rural or underserved areas to access advanced neurological care without traveling long distances. Digital therapeutics solutions, which include apps for symptom tracking and therapy adherence, can be used anywhere, bridging gaps in access to specialized care.

Digital therapeutics are designed to engage patients by offering tools like self-management apps, reminders, and personalized interventions. This improves patient adherence to therapy regimens, especially in chronic neurological conditions that require long-term management. The interactive and gamified nature of many digital solutions boosts engagement, making it easier for patients to stick with prescribed therapy regimens and track their progress regularly.

For instance, in October 2023, BeCareLink introduced a new quantitative and artificial intelligence (AI)-enabled app to support general neurologic exams for the screening and monitoring of neurologic diseases. Called BeCare Neuro Link, the new mobile application is intended for the remote, objective and comprehensive assessment of neurologic patients or those with potential neurologic conditions.

Data Privacy & Cybersecurity Concerns

Data privacy and cybersecurity are major concerns in the digital therapeutics for neurological disorders market, as these platforms rely on the collection, storage and analysis of sensitive patient data, including personal health information (PHI), cognitive assessments, and real-time health monitoring. Digital therapeutics platforms often store patient data in cloud-based systems or other online infrastructures, making them vulnerable to cyberattacks. A breach of sensitive health data could result in identity theft, financial fraud, or even medical fraud.

For instance, according to the HIPAA Journal, in August 2023, 23 million breached healthcare records are noticed. Over the past 12 months, an average of 9,989,003 healthcare records were breached each month. In the year to August 31, 2024, there have been 491 data breaches of 500 or more records, and at least 58,668,002 records are known to have been breached. The average breach size in 2024 is currently 119,487 records and the median breach size is 4,109 records.

Segment Analysis

The global digital therapeutics for neurological disorders market is segmented based on product type, disease type, end-user and region.

Product Type:

The software therapeutics from the product type segment are expected to dominate the global digital therapeutics for neurological disorders market

Software therapeutics, primarily through mobile applications and web-based platforms, are accessible anytime, anywhere, making them a convenient option for patients. This ease of use is a major reason why software-based digital therapeutics are preferred in home-based care scenarios, especially for neurological conditions where ongoing management is required.

For instance, Cogstate's Cognigram is a software platform that provides cognitive testing for people with Alzheimer's disease and mild cognitive impairment. This platform enables patients to track cognitive performance remotely and interact with their healthcare provider, offering a more convenient and accessible solution than traditional in-clinic testing.

Software therapeutics are generally more cost-effective compared to traditional treatments that involve frequent doctor visits, hospitalizations, or long-term medication. By offering at-home solutions and reducing the need for in-person consultations, software therapeutics can lower the overall healthcare costs for both patients and healthcare providers. For instance, Pear Therapeutics' reSET-O, a prescription digital therapeutic for opioid use disorder, is an FDA-approved software solution that reduces the need for continuous in-person visits and provides remote support.

Geographical Analysis

North America is expected to hold a significant position in the global digital therapeutics for neurological disorders market

North America, and particularly the United States, benefits from a well-established regulatory framework through the FDA (Food and Drug Administration), which has streamlined the approval process for digital therapeutics. This regulatory clarity boosts market confidence and accelerates the adoption of digital therapeutics solutions for neurological disorders. For instance, The FDA's Digital Health Innovation Action Plan aims to promote innovation and expedite the approval of digital therapeutics. The approval of products like EndeavorRx (for ADHD) and reSET (for addiction treatment) demonstrates the regulatory readiness in North America to approve digital solutions for treating neurological conditions.

The prevalence of neurological disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and epilepsy is rising in North America, driving the demand for digital therapeutics. The aging population in the United States and Canada is a major factor contributing to this increase. The number of people diagnosed with Alzheimer's is expected to grow significantly in North America due to the aging Baby Boomer population.

Digital therapeutic platforms that provide cognitive training, symptom tracking, and remote monitoring are increasingly sought after to manage the long-term care needs of these patients. For instance, according to the Alzheimer's Association, in the U.S. alone, 5.8 million people were living with Alzheimer's disease in 2020, and that number is expected to double by 2060. As the number of patients increases, so does the demand for digital health solutions to manage these conditions.

Competitive Landscape

The major global players in the digital therapeutics for neurological disorders market include Akili, Inc., Click Therapeutics, Inc., BigHealth, Apple Inc., MindMaze Inc, NeuroPace, Inc., NeurologyToolKit, Matoph Labs e.U., Fullpower Technologies, Inc., Neybox Digital Ltd. and among others.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global digital therapeutics for neurological disorders market report delivers a detailed analysis with 62 key tables, more than 56 visually impactful figures and 166 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

• 1.1. Objectives of the Report
• 1.2. Report Coverage & Definitions
• 1.3. Report Scope

2. Executive Insights and Key Takeaways

• 2.1. Market Highlights and Strategic Takeaways
• 2.2. Key Trends and Future Projections
• 2.3. Snippet by Product Type
• 2.4. Snippet by Disease Type
• 2.5. Snippet by End-User
• 2.6. Snippet by Region

3. Dynamics

• 3.1. Impacting Factors
  • 3.1.1. Drivers
    • 3.1.1.1. Shift Towards Home-Based Care & Remote Patient Monitoring
    • 3.1.1.2. Rising Prevalence of Neurological Disorders
  • 3.1.2. Restraints
    • 3.1.2.1. Data Privacy & Cybersecurity Concerns
    • 3.1.2.2. Patient Adherence & Engagement Challenges
  • 3.1.3. Opportunity
    • 3.1.3.1. Rising Technological Advancements
  • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

• 4.1. Market Leaders and Pioneers
  • 4.1.1. Emerging Pioneers and Prominent Players
  • 4.1.2. Established Leaders with Largest Selling Brand
  • 4.1.3. Market Leaders with Established Product
• 4.2. CXO Perspectives
• 4.3. Latest Developments and Breakthroughs
• 4.4. Case Studies/Ongoing Research
• 4.5. Regulatory and Reimbursement Landscape
  • 4.5.1. North America
  • 4.5.2. Europe
  • 4.5.3. Asia Pacific
  • 4.5.4. Latin America
  • 4.5.5. Middle East & Africa
• 4.6. Porter's Five Force Analysis
• 4.7. Supply Chain Analysis
• 4.8. Patent Analysis
• 4.9. SWOT Analysis
• 4.10. Unmet Needs and Gaps
• 4.11. Recommended Strategies for Market Entry and Expansion
• 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
• 4.13. Pricing Analysis and Price Dynamics
• 4.14. Key Opinion Leaders

5. Digital Therapeutics for Neurological Disorders Market, By Product Type

• 5.1. Introduction
  • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 5.1.2. Market Attractiveness Index, By Product Type
• 5.2. Software Therapeutics*
  • 5.2.1. Introduction
  • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 5.3. Wearable Devices

6. Digital Therapeutics for Neurological Disorders Market, By Disease Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 6.1.2. Market Attractiveness Index, By Disease Type
• 6.2. Neurodegenerative Disorders*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.2.3. Alzheimer's Disease
  • 6.2.4. Parkinson's Disease
  • 6.2.5. Multiple Sclerosis
  • 6.2.6. Huntington's Disease
  • 6.2.7. Others
• 6.3. Mental Health Disorders
  • 6.3.1. Depression
  • 6.3.2. Anxiety
  • 6.3.3. Post-Traumatic Stress Disorder
  • 6.3.4. Bipolar Disorder
  • 6.3.5. Obsessive-Compulsive Disorder (OCD)
  • 6.3.6. Others
• 6.4. Stroke & Cerebrovascular Disorders
• 6.5. Sleep Disorders
  • 6.5.1. Insomnia
  • 6.5.2. Sleep Apnea
  • 6.5.3. Others
• 6.6. Cognitive Disorders
• 6.7. Others

7. Digital Therapeutics for Neurological Disorders Market, By End-User

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 7.1.2. Market Attractiveness Index, By End-User
• 7.2. Hospitals*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Specialty Clinics
• 7.4. Neuro-Rehabilitation Centers
• 7.5. Homecare Settings
• 7.6. Others

8. Digital Therapeutics for Neurological Disorders Market, By Regional Market Analysis and Growth Opportunities

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 8.1.2. Market Attractiveness Index, By Region
• 8.2. North America
  • 8.2.1. Introduction
  • 8.2.2. Key Region-Specific Dynamics
  • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.2.6.1. U.S.
    • 8.2.6.2. Canada
• 8.3. Europe
  • 8.3.1. Introduction
  • 8.3.2. Key Region-Specific Dynamics
  • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.3.6.1. Germany
    • 8.3.6.2. U.K.
    • 8.3.6.3. France
    • 8.3.6.4. Spain
    • 8.3.6.5. Italy
    • 8.3.6.6. Rest of Europe
• 8.4. Latin America
  • 8.4.1. Introduction
  • 8.4.2. Key Region-Specific Dynamics
  • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.4.6.1. Mexico
    • 8.4.6.2. Brazil
    • 8.4.6.3. Argentina
    • 8.4.6.4. Rest of Latin America
• 8.5. Asia-Pacific
  • 8.5.1. Introduction
  • 8.5.2. Key Region-Specific Dynamics
  • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.5.6.1. China
    • 8.5.6.2. India
    • 8.5.6.3. Japan
    • 8.5.6.4. South Korea
    • 8.5.6.5. Rest of Asia-Pacific
• 8.6. Middle East and Africa
  • 8.6.1. Introduction
  • 8.6.2. Key Region-Specific Dynamics
  • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

• 9.1. Competitive Overview and Key Market Players
• 9.2. Market Share Analysis and Positioning Matrix
• 9.3. Strategic Partnerships, Mergers & Acquisitions
• 9.4. Key Developments in Product Portfolios and Innovations
• 9.5. Company Benchmarking

10. Company Profiles

• 10.1. Akili, Inc.*
  • 10.1.1. Company Overview
  • 10.1.2. Product Portfolio
    • 10.1.2.1. Product Description
    • 10.1.2.2. Product Key Performance Indicators (KPIs)
    • 10.1.2.3. Historic and Forecasted Product Sales
    • 10.1.2.4. Product Sales Volume
  • 10.1.3. Financial Overview
    • 10.1.3.1. Company Revenue's
    • 10.1.3.2. Geographical Revenue Shares
    • 10.1.3.3. Revenue Forecasts
  • 10.1.4. Key Developments
    • 10.1.4.1. Mergers & Acquisitions
    • 10.1.4.2. Key Product Development Activities
    • 10.1.4.3. Regulatory Approvals, etc.
  • 10.1.5. SWOT Analysis
• 10.2. Click Therapeutics, Inc.
• 10.3. BigHealth
• 10.4. Apple Inc.
• 10.5. MindMaze Inc
• 10.6. NeuroPace, Inc.
• 10.7. NeurologyToolKit
• 10.8. Matoph Labs e.U.
• 10.9. Fullpower Technologies, Inc.
• 10.10. Neybox Digital Ltd.

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

• 11.1. Data Collection Methods
• 11.2. Data Triangulation
• 11.3. Forecasting Techniques
• 11.4. Data Verification and Validation

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us